华恒生物(688639) - 2021 Q3 - 季度财报
AHBAHB(SH:688639)2021-10-27 16:00

Financial Performance - The company's operating revenue for Q3 2021 was ¥241,517,087.57, representing a year-on-year increase of 136.56%[4] - The net profit attributable to shareholders for Q3 2021 was ¥39,947,934.94, up 96.06% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥34,573,906.00, reflecting a 142.68% increase year-on-year[4] - Total operating revenue for Q3 2021 reached ¥621,155,770.65, a significant increase from ¥360,559,544.17 in Q3 2020, representing a growth of approximately 72.4%[17] - Net profit for Q3 2021 was ¥102,080,752.55, compared to ¥85,170,267.16 in Q3 2020, reflecting an increase of about 19.8%[18] - Operating profit for Q3 2021 was ¥111,081,485.28, up from ¥97,565,067.97 in the same quarter last year, indicating a growth of approximately 13.9%[18] Research and Development - The total R&D investment for Q3 2021 was ¥14,097,126.21, which is a 103.57% increase compared to the same period last year[5] - Research and development expenses for Q3 2021 totaled ¥33,241,754.32, compared to ¥24,765,889.86 in Q3 2020, marking an increase of about 34.1%[17] - The company plans to continue expanding its market presence and investing in R&D to support future growth[8] Assets and Liabilities - The total assets at the end of Q3 2021 reached ¥1,366,397,530.53, marking an 83.93% increase from the end of the previous year[5] - The equity attributable to shareholders at the end of Q3 2021 was ¥1,099,634,918.85, showing a 124.52% increase year-on-year[5] - The company's total current assets reached RMB 822,424,911.49, compared to RMB 261,582,018.88 in the previous year, indicating a growth of about 214.5%[14] - The total liabilities of the company were RMB 266,762,611.68, up from RMB 253,105,456.17, reflecting a rise of about 5.5%[16] - The company’s total liabilities to total assets ratio was approximately 19.5%, indicating a relatively low leverage position[16] Cash Flow - The company reported a net cash flow from operating activities of ¥80,064,950.60 for the year-to-date period, reflecting a 1.52% increase year-on-year[4] - Cash flow from operating activities for Q3 2021 was ¥80,064,950.60, slightly up from ¥78,865,335.59 in Q3 2020[21] - Cash inflow from investment activities in Q3 2021 was ¥245,194,527.19, compared to ¥1,051,366.30 in Q3 2020, showing a substantial increase[21] - Total cash outflow from investment activities for Q3 2021 was ¥705,345,715.99, compared to ¥45,814,550.41 in Q3 2020, indicating a significant rise[21] - Cash flow from financing activities in Q3 2021 amounted to ¥643,739,010.00, compared to ¥71,000,000.00 in Q3 2020, reflecting a notable increase[21] - The net cash flow from financing activities was $483,562,281.58, a significant increase compared to the previous year's negative cash flow of $19,082,469.73[22] - The total cash and cash equivalents at the end of the period reached $163,094,016.23, up from $61,159,541.22 in the same quarter last year, indicating a net increase of $103,419,622.79[22] Inventory and Receivables - The company reported a significant increase in accounts receivable, which rose to RMB 163,701,455.07 from RMB 88,488,236.47, representing an increase of about 84.9%[14] - The company's inventory was reported at RMB 68,975,202.10, compared to RMB 47,106,045.83 in the previous year, indicating an increase of approximately 46.5%[14] Earnings Per Share - The basic earnings per share for Q3 2021 was ¥0.37, an increase of 47.05% compared to the same period last year[5] - Basic earnings per share for Q3 2021 were ¥1.06, slightly higher than ¥1.05 in Q3 2020[19] Other Information - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[12] - The company has adopted the new leasing standards effective January 1, 2021, but it does not involve adjustments to the opening balance of related financial statement items[22]